Skip to main content
Download PDF

LFA-1 knockout inhibited the tumor growth and is correlated with treg cells

Cell Communication and Signaling volume 21, Article number: 233 (2023) Cite this article

Abstract

Cancer immunotherapy has been proven to be clinically effective in multiple types of cancers. Lymphocyte function-associated antigen 1 (LFA-1), a member of the integrin family of adhesion molecules, is expressed mainly on αβ T cells. LFA-1 is associated with tumor immune responses, but its exact mechanism remains unknown. Here, two kinds of mice tumor model of LFA-1 knockout (LFA-1−/−) mice bearing subcutaneous tumor and Apc Min/+;LFA-1−/− mice were used to confirm that LFA-1 knockout resulted in inhibition of tumor growth. Furthermore, it also demonstrated that the numbers of regulatory T cells (Treg cells) in the spleen, blood, mesenteric lymph nodes were decreased in LFA-1−/− mice, and the numbers of Treg cells in mesenteric lymph nodes were also decreased in Apc Min/+;LFA-1−/− mice compared with Apc Min/+ mice. LFA-1 inhibitor (BIRT377) was administered to subcutaneous tumor-bearing LFA-1+/+ mice, and the results showed that the tumor growth was inhibited and the number of Treg cells was reduced. The analysis of TIMER tumor database indicated that LFA-1 expression is positively associated with Treg cells and TNM stage. Conclusively, this suggests that LFA-1 knockout would inhibit tumor growth and is correlated with Treg cells. LFA-1 may be one potential target for cancer immunotherapy.

Video Abstract

Introduction

Lymphocyte function-associated antigen 1 (LFA-1), also known as Itgal, is composed of an αL subunit (CD11a) and a β2 subunit (CD18), which form a heterodimer expressed on the surface of all leukocytes, including T cells, B cells, macrophages, and neutrophils [1]. Previous studies have shown that LFA-1 affects hematologic malignancies or tumor invasion and is involved in angiogenesis, leukocyte recruitment, and migration [2, 3]. However, the role of LFA-1 in tumor development and growth remains unclear. Studies showed that the severity of experimental autoimmune encephalomyelitis (EAE) increased after wild-type T cells were transplanted into LFA-1−/− recipient mice with encephalitis and that the Treg cell count in the spleen and thymus of these mice were lower than those in LFA-1+/+ mice, which indicated that the development of Treg cells was altered. LFA-1 has both proinflammatory and anti-inflammatory roles in the pathogenesis of EAE [4, 5]. The exacerbation of EAE progression in LFA-1−/− mice may be due to impaired inhibition of autoantigen-specific effector T cells by Treg cells, which present a normal Cytoxic T-cell lymphocyte (CTL) response to viral infection but fail to reject immunogenic tumors grafted into the footpads [5, 6].

Some studies suggested that Treg cells could be a target for cancer therapy [7, 8], and play a key role in preventing autoimmunity, limiting immunopathology, and maintaining immune homeostasis. LFA-1 participates in the recruitment, adhesion, and migration of various immune cells [9, 10], activities that are especially necessary for the transport of T cells to mesenteric lymph nodes and the homing of effector T cells to the colon, which causes chronic intestinal inflammation in the colon [11].

Familial adenomatous polyposis and colorectal cancer are autosomal dominant diseases caused by genetic mutation of the adenomatous polyposis (APC) gene located on chromosome 5p21. Mutation occurs at many different sites of APC gene [12,13,14]. Treg cells were shown to delay the growth of intestinal tumors in APC Min/+ mice by suppressing intestinal inflammation [15,16,17]. Apc Min/+ mice exhibit stable heredity and spontaneous development of intestinal adenomas and have been extensively used in tumor immunity and cancer drug discovery.

In our study, we found that LFA-1 knockout suppresses the growth of intestinal tumors in Apc Min/+ mice and subcutaneous xenograft tumor growth in LFA-1−/− mice, and the Treg cells were decreased in spleen and blood in mice. BIRT377 is an LFA-1 noncompetitive inhibitor targeting the active conformation of a transmembrane β-2 adhesion receptor that reduces the expression of LFA-1 on white blood cells [18]. BIRT377, which selectively inhibits LFA-1/ICAM-1 mediated binding events in vitro and in vivo, blocks the interaction between T cells and antigen-presenting cells (referred to as an immune synapse) [19]. BIRT377 was used to treat subcutaneous tumor-bearing LFA-1+/+ mice, and it can effectively slow down the growth of tumors and down-regulate Treg cells.

In summary, the regulation of Treg cells by LFA-1 knockout might be the main reason for inhibiting tumor growth. Characterization and identification of the function of LFA-1 would facilitate the restoration of immune function in cancer patients and even contribute to the clinical potential of immunotherapy.

Materials and methods

Mice

The APC transgenic mice and Apc Min/+ and LFA-1-deficient mice (LFA-1−/−) were purchased from The Jackson Laboratory (C57BL/6J-Apc Min/+/J and B6.129S7-Itgaltm1Bll/J, respectively). In our study, Apc Min/+;LFA-1−/− mice were obtained by crossbreeding Apc Min/+ mice with LFA-1−/− mice. After cutting off some toes of mice, tissue DNA was extracted by alkali lysis method, and the genotype was identified by PCR amplification. Apc Min/+ primer sequence of gene fragment: Mutant primer: 5’-TTC TGA GAA AGA CAG AAG TTA-3’, Wild-type primer: 5’-TTC CAC TTT GGC ATA AGG C-3’, Common primer: 5’-GCC ATC CCT TCA CGT TAG-3’. LFA-1 mutant primer1: 5’-GCC CTG AAT GAA CTG CAG GAC G-3’, LFA-1 mutant primer2: 5’-CAC GGG TAG CCA ACG CTA TGT C-3’, LFA-1 wild-type primer1: 5’-AGA AGC CAC CAT TTC CCT CT-3’, LFA-1 wild-type primer2: 5’-AGC TGG AGT CCC AGT AGC AA-3’. After carrying out agarose gel electrophoresis on PCR amplification products. The amplified fragment of APC gene mutation primer PCR product is 340 bp, the amplified fragment of APC gene wild-type primer PCR product is 600 bp. Apc Min/+ mice are heterozygotes, with mutation bands (340 bp) and wild-type bands (600 bp) double bands in genotype identification. The amplification fragment of LFA-1 gene Mutant primer PCR product is 432 bp, the amplification fragment of LFA-1 gene wild-type primer PCR product is 151 bp. LFA-1−/− mice are homozygous for mutation, and genotyping shows that there are only mutant bands (432 bp) but no wild-type bands (151 bp). Apc Min/+;LFA-1−/− mice were screened after the third generation hybridization (Supplemental Fig. 1A). C57BL/6J mice were obtained from the Guangdong Medical Laboratory Animal Center, Guangzhou, China. All mice were housed in the specific pathogen-free barrier facility of the Animal Center of Guangdong Pharmaceutical University (license number SCYK (Guangdong) 2017 − 0125). All mice were sacrificed by dislocating the cervical vertebrae. The Animal Ethics Review Committee approved all Guangdong Pharmaceutical University animal experiments; the number of animal ethics approval was Gdpulac20177006.

Cell culture

B16F10 melanoma cells (Shanghai Institute of Cell Biology, Chinese Academy of Sciences) were maintained in high-glucose Dulbecco’s modified Eagle’s medium (Invitrogen) containing 10% fetal bovine serum (FBS; GIBCO). The cell was incubated in a humidified chamber containing 5% CO2 at 37 °C, and it was confirmed with no mycoplasma contamination by PCR detection.

Subcutaneous tumor xenograft models

B16F10 melanoma cells (2 × 105 cells per mouse) were injected subcutaneously into LFA-1−/− mice (n = 11) and LFA-1+/+ mice (n = 16) in the lower right groin. Mouse tumor growth and body weight were monitored and recorded once a day. After 2 weeks, these mice were sacrificed, and their blood, tumor tissues, and spleens were harvested and preserved for further analysis.

Intestinal tumor mouse model

Male Apc Min/+ mice and female LFA-1−/− mice aged from 12 to 24 weeks were caged for breeding at a ratio of 1:3. Next, male Apc Min/+;LFA-1+/− mice from the first generation were selected for breeding with age-appropriate female LFA-1−/− mice to obtain the second generation. Apc Min/+;LFA-1−/− mice from the second generation were identified and were then reared under a hybrid spontaneous intestinal adenoma model for subsequent experimental research (Supplemental Fig. 1A). Survival status and intestinal tumor growth were observed in all Apc Min/+;LFA-1−/− mice (n = 25) and Apc Min/+ mice (n = 32). From birth to 48 weeks of age, the Apc Min/+;LFA-1−/− mice did not exhibit prominent physiological or histopathological abnormalities, exhibiting only weight loss without a change in the spleen-to-weight ratio (Supplemental Fig. 1B). After the mice were sacrificed, the intestines were harvested, and the length (L) and width (W) of the tumors were measured. Adenomas were considered to have a diameter > 2 mm; microadenomas, a diameter ≤ 2 mm. The tumor volume was calculated as V = 0.5×L×W2.

BIRT377 treatment

BIRT377 (Tocris; Cat# 4776) was dissolved in anhydrous ethanol to a concentration of 22.156 mg/mL and stored at 4 ℃. The vehicle was sterile water containing 0.226% ethanol. On the day of injection, the vehicle was heated in a water bath at 37 ℃, and BIRT377 was added to a concentration of 500 ng/20 µL for i.v. injection [20]. Animals were injected within one hour of BIRT377 dilution. B16 tumor-bearing LFA-1+/+ mice were divided into two groups. On the 7th day, when the tumors were observed, BIRT377 (20 µL per mouse) was injected through the tail vein into mice in the experimental group (n = 13), and mice in the control group (n = 10) were injected with 20 µL of vehicle. The total operation time of the injection was less than 2 min without anesthesia. All mice appeared normal following the injection. According to the above methods of injection once a day, 7 days of continuous injection, the mice were euthanized, and the subcutaneous tumors and spleen tissues were then excised for subsequent analysis.

H&E and IHC

4% Formalin-fixed, paraffin-embedded tissues were prepared. After deparaffinization, 3 μm sections were stained with hematoxylin for 3 min and eosin for 30 s and were then dried and sealed with neutral resin. IHC staining was performed as described on the Abcam website. Antigen retrieval was carried out in citrate buffer (pH 6.0). Sections were incubated with a primary antibody overnight at 4 ℃. Next, sections were incubated with a secondary antibody for 1 h at 37 ℃, and color was developed with DAB (8059 S, CST, USA) chromogenic solution. The primary antibodies included anti-Ki67 (1:100, ab16667, Abcam, USA), anti-CD31 (1:100, ab28364, Abcam, USA), and anti-Foxp3 (1:100, BA2032-1, Boster, China) antibodies. The HRP-conjugated anti-rabbit/mouse secondary antibody was obtained from DAKO. According to the diagnostic guidelines, three pathologists independently scored the HE sections of the intestinal tract tissues. The number of ki67 positive cells was counted and compared. The area of CD31 positive expression was calculated, and the microvascular density (MVD) was compared. Statistical analysis of immunohistochemical staining was performed using IPP6.0 software.

RNA sequencing

The spleens of LFA-1−/− mice (n = 4) and LFA-1+/+ mice (n = 4) were frozen in liquid nitrogen. Total RNA of spleen tissue was extracted by Beijing Genomics Institute (BGI, Wuhan, China) to construct the cDNA library, which was sequenced on the Illumina sequencing platform. The DESeq algorithm was utilized to filter the differentially expressed genes.

Flow cytometry analysis

FACS analysis was carried out on the blood and tissue samples on a Beckman Coulter Gallios Flow Cytometer. Antibodies specific for the following cell surface markers were used: CD3 conjugated to PerCP-Cy5.5 (clone: 145-2C11), CD4 conjugated to PE (clone: GK1.5), CD8 conjugated to BV421 (clone: 53 − 6.7), and CD25 conjugated to APC (clone: PC61). Moreover, the measurement of intracellular signaling molecules (Alexa Fluor® 488 anti-mouse/rat/human FOXP3 antibody, clone: 150D, BioLegend, USA) was performed for Foxp3 analysis. Each experiment included single-color compensation and an appropriate isotype control, and each sample was independently analyzed at least three times. As evaluated by the mean fluorescence intensity, the percentage of positive cells was determined with FlowJo software (Tree Star, Inc. OR, USA). Lymphocytes were identified by plotting forward vs. side scatter followed by gating on CD3 + T cells, and these cells were then analyzed by separation into CD4 + T and CD8 + T cells. Treg cells were identified as CD25 + Foxp3 + cells gated within CD3 + CD4 + T cells.

RNA isolation and real-time PCR

Total RNA was extracted from blood, spleens, and mesenteric lymph nodes with TRIzol reagent (Invitrogen, USA) according to the instructions. All reverse transcription reactions were set up using an EVO M-MLV RT Kit (Accurate Biology, China). Real-time quantitative PCR was performed with a SYBR® Green Premix Pro Taq HS qPCR Kit (Accurate Biology, China) on an Applied Biosystems 7500 instrument. The thermal cycling conditions for PCR were as follows: 95 °C for 3 min, followed by 40 cycles at 95 °C for 30 s, 58 °C for 40 s and 72 °C for 50 s, and a final 10 min extension at 72 °C. The PCR primers are listed in Table 1 (Supplementary data).

Statistical analysis

Data are shown as the mean ± standard deviation (SD) values. The Kaplan–Meier method with the log-rank test were used for survival analysis (GraphPad Prism 5). IHC images were analyzed with IPP6.0 software. The Pearson chi-square test was used to compare the IHC scores. Student’s t test was used to analyze the real-time PCR results. A p value less than 0.05 was considered statistically significant.

Results

LFA-1 knockout suppressed tumor growth in mice

LFA-1 is a lymphocyte-associated antigen that plays a critical role in inflammation, and regulating immune cells. We established a subcutaneous xenograft tumor model to investigate whether LFA-1 knockout affects tumor growth. Next, the survival rates, body weight, and tumor growth of the mice were recorded after two weeks. The results showed that compared to that in LFA-1+/+ +B16 mice (n = 7), the tumor volume in LFA-1−/− mice (n = 7) was significantly reduced (Fig. 1A**P < 0.01) and the tumor-to-body weight ratio was also reduced between the two groups (Fig. 1B, **P < 0.01). To confirm that pathological processes involved in tumor growth, IHC staining was carried out with anti-Ki67 antibody and anti-CD31 antibody. The results indicated that LFA-1−/− mice exhibited lower tumor cell proliferation and a lower microvascular density (MVD) than control mice (Fig. 1C-F, *P < 0.05), which implies that tumor growth was suppressed in LFA-1 knockout mice.

Fig. 1
figure 1

LFA-1 deletion inhibited subcutaneous tumor growth. A Comparison and statistics of subcutaneous tumor volume between LFA-1−/− mice (n = 7) and LFA-1+/+ mice (n = 7) (**P < 0.001). B LFA-1−/− mice (n = 7) and LFA-1+/+ mice (n = 7) tumor-to-body weight ratio (**P < 0.001). C Immunohistochemical staining of Ki67 antibody in subcutaneous melanoma in mice. D Proliferation rate in subcutaneous tumors of LFA-1−/− mice (n = 3) and LFA-1+/+ mice (n = 3). E Immunohistochemical staining of CD31 antibody in subcutaneous melanoma in mice. F The intratumoral microvessel density (MVD) in subcutaneous tumors of LFA-1−/− mice (n = 3) and LFA-1+/+ mice (n = 3)

Full size image

Using another intestinal tumor mice model, we compared the tumor numbers, tumor volumes and survival rates between Apc Min/+ mice (n = 10) and Apc Min/+;LFA-1−/− mice (n = 11). The results also showed that the tumor numbers in Apc Min/+;LFA-1−/− mice were reduced compared to those in Apc Min/+ mice (Fig. 2A, **P < 0.01, *P < 0.05) at 15 weeks,. Especially, the volumes of microadenomas and adenomas were lower in Apc Min/+;LFA-1−/− mice than in Apc Min/+ mice (Fig. 2A, right; **P < 0.01, *P < 0.05). The survival rate was dramatically increased in Apc Min/+;LFA-1−/− mice (Fig. 2B, **P < 0.01).

Fig. 2
figure 2

LFA-1 knockout inhibits intestinal tumor growth in Apc Min/+;LFA-1−/−mice. A The number and volume of intestinal microadenoma and adenoma were reduced in Apc Min/+;LFA-1−/− mice (n = 11) than in Apc Min/+ mice (n = 10) (**, P < 0.01, *P < 0.05, microadenoma diameter ≤ 2 mm; adenoma diameter > 2 mm). B The survival rate of Apc Min/+;LFA-1−/− mice(n = 25) was higher than Apc Min/+ mice(n = 32) after being assessed by Kaplan-Meier analysis with SPSS software. C&D H&E staining and scoring of intestinal malignancy in Apc Min/+ mice (n = 4) and Apc Min/+;LFA-1−/− mice (n = 4) (The area in the red box is the area of intestinal gland obstruction). E&G Ki67 and CD31 histochemistry showed the process of tumor proliferation and MVD in Apc Min/+ mice (n = 4) and Apc Min/+;LFA-1−/− mice (n = 4). F The index of tumor proliferation in Apc Min/+ mice (n = 4) were slow than Apc Min/+;LFA-1−/− mice (n = 4, *P < 0.05). H. The MVD in Apc Min/+ mice (n = 4) were less than Apc Min/+;LFA-1−/− mice (n = 4, *P < 0.05)

Full size image

We also performed pathological IHC staining. The score of the H&E staining showed that LFA-1 knockout slowed down intestinal gland obstruction and alleviated inflammation (Fig. 2C&D, *P < 0.05). Meantime, the growth and infiltration of tumor was assessed using IHC staining, which presented less tumor cell proliferation index Ki67 (Fig. 2E&F, *P < 0.05) and lower microvascular density index CD31 (Fig. 2G&H, *P < 0.05) in Apc Min/+;LFA-1−/− mice compared with Apc Min/+ mice. These two results suggest that LFA-1 knockout suppresses both endogenous and graft tumor growth.

The numbers of Treg cells were decreased in LFA-1−/− mice

The above results showed that LFA-1 knockout suppressed tumor growth. To analyze the role of LFA-1 in the tumor immune response, sequence analysis of spleen mRNA showed that LFA-1 knockout resulted in upregulation of 268 genes and downregulation of 115 genes, most of which were related to immune system diseases and tumor immune (Fig. 3A&B). T-lymphocyte is an important component of immune cells. We analyzed the T-lymphocyte subtype-related markers of immune cells including Th1, Th2, Th17 and Thf cells, some of which were up-regulated and some were down-regulated (data not shown). Meanwhile the markers related to Treg cell, including secretory factors, cell membrane genes, and nuclear transcription factor genes, are out of balance. Foxp3 is the most critical transcription factor in Treg cells. By analyzing the value of log2Ratio (LFA-1−/−/Control), it was found that the expression level of Foxp3 mRNA was significantly down-regulated (Fig. 3C).

Fig. 3
figure 3

LFA-1 knockout down-regulated Treg cells. A The results of spleen mRNA sequencing showed that LFA-1 knockout up-regulated 268 genes and down-regulated 115 genes. B Sequencing results showed 31 genes related to cancer overview, 27 genes related to immune diseases, and 62 genes related to the immune system. C The Treg cell-related genes were analyzed by spleen mRNA sequencing, and the change of Foxp3 was significant (n = 4). D-G The representative image of Treg flow results in blood, spleen, and mesenteric lymph nodes in LFA-1−/− + B16 mice (n = 5) and LFA-1+/+ + B16 mice (n = 5). Treg cells in mesenteric lymph nodes in Apc Min/+ mice (n = 4) were lower than Apc Min/+;LFA-1−/− mice (n = 4). H-J The percentage of Treg cells in blood, spleen, and mesenteric lymph nodes of LFA-1−/− + B16 mice and LFA-1+/+ +B16 mice (n = 5, *P < 0.05, **P < 0.01).The number of Treg cells in the mesenteric lymph nodes of Apc Min/+;LFA-1−/− mice was measured by flow cytometry and counted (n = 4, *P < 0.05)

Full size image

To further confirm that Foxp3 expression was altered in the spleens of mice, we performed IHC staining using Foxp3 antibody on spleen tissue from LFA-1−/− mice. Compared to LFA-1+/+ mice, the distribution of Foxp3-positive cells in the spleens of LFA-1−/− mice was lower in the white pulp splenic corpuscle (Supplementary Fig. 2A&C, *P < 0.05). And we further stained the spleen tissue of subcutaneous tumor-bearing mice with a Foxp3 antibody. The results also showed that the expression of Foxp3 was less in the white pulp of the spleen of LFA-1−/− tumor-bearing mice (Supplementary Fig. 2B&D, *P < 0.05).

Treg cells can inactivate or regulate T cells, including CD4 + T and CD8 + T cells [21,22,23]. Circulating CD4 + T and CD8 + T lymphocytes in the blood play an essential role in immune function, and LFA-1 is a key regulator of these functions of T cells. Treg cells were further detected by FCM with anti-Foxp3 and anti-CD25 antibodies and gating on naive CD4 cells. First, we determined the numbers of Treg cells in the blood, spleens and lymph nodes of non-tumor-bearing mice by FCM. The results showed that the decrease of CD4 + CD25 + Foxp3 + Treg cells was significantly different in the blood and lymph nodes (Supplementary Fig. 2E-J; **P < 0.01, *P < 0.05). We also detected the changes in Treg cells in the subcutaneous tumor-bearing model, and the results showed that LFA-1 knockout decreased the numbers of CD4 + CD25 + Foxp3 + Treg cells in the blood, spleens, and lymph nodes (Fig. 3D-F H-J; **P < 0.01, *P < 0.05). There was a significant decrease in the number of Treg cells in tumor-bearing LFA−/− mice.

In addition, we counted CD4 + CD25 + Foxp3 + Treg cells in Apc Min/+ mice and Apc Min/+;LFA-1−/− mice. The results showed that the percentage of CD4 + CD25 + Foxp3 + Treg cells was decreased in mesenteric lymph nodes in Apc Min/+;LFA-1−/− mice (Fig. 3G&K, *P < 0.05). The absolute numbers of Treg cells were also consistent with the percentages of Treg cells (data not shown). The cytokines IL-10, IL-17, and IFN-γ are the key mediators involved in suppressing the growth of tumor cells, IFN-γ, IL-10, and IL-17 production was increased in the spleen of LFA-1-deficient mice, suggesting that tumor immunity was unbalance or enhanced [24]. We also found that the expression levels of IFN-γ and IL-17 in blood of Apc Min/+;LFA-1−/− mice increased, and the expression levels of IFN-γ, IL-10, and IL-17 in spleen of Apc Min/+;LFA-1−/− mice increased compared to Apc Min/+ mice, but there was no premonitory increase in mesentery lymph nodes(Supplementary Fig. 1C-E, *P < 0.05, **P < 0.01). In short, LFA-1 gene knockout affected the expression of Treg cells gene, reduced the number of Treg cells and changed the expression level of some cytokines.

LFA-1 inhibitor suppressed tumor growth and decreased the numbers of Treg cells

BIRT377 is a potent negative allosteric modulator of LFA-1 that binds to the I-domain of LFA-1 as an LFA-1 inhibitor. It has been shown to reduce CD3 + T cells aggregation [19] and can promote degranulation of NK cells [25]. To investigate the role of LFA-1 inhibition in tumor development, mice were treated with BIRT377, and the solvent was used as the control. The results showed the tumor growth was significantly inhibited in the BIRT377 treated group (Fig. 4A) and that the ratio of tumor weight to body weight was significantly decreased (Fig. 4B left, *P < 0.05); in addition, the tumor volume showed a decreasing trend (Fig. 4B middle, *P < 0.05), and the body weights of the mice did not appear in the BIRT377 treated group (n = 13) than the control group (n = 10; Fig. 4B, right). The drug did not cause other damage to mice, and there were no changes in fur color, food intake or other vital signs. Furthermore, we examined cell proliferation and the microvascular density index in tumor tissues. The results showed that cell proliferation and the microvascular density were lower in the BIRT377 treated group (n = 3) than in the control group (n = 3; Fig. 4C-F; *P < 0.05, **P < 0.01). Next, we detected Treg cells in the peripheral blood, mesenteric lymph nodes and spleen by flow cytometry and found that the numbers of Treg cells were significantly decreased in the BIRT377 treated group (n = 5) compared with the control group (n = 4) (Fig. 4G-L, **P < 0.01). Therefore, our data suggest that BIRT377 blocks LFA-1, decreases the Treg cells population, and inhibits mouse tumor growth.

Fig. 4
figure 4

BIRT377 treatment suppressed tumor growth and down-regulate Treg in the spleen. A The administration of BIRT377 inhibits the growth of subcutaneous tumors. B The subcutaneous tumor weight/bodyweight of the BIRT377 group (n = 10) and control group (n = 8, *P < 0.05), and the tumor volume of the BIRT377 group (n = 10) were smaller than that of control (n = 8, *P < 0.05), but the body weight of the BIRT377 group (n = 13) compare to control (n = 10), it is no statistical difference. C&E Ki67 antibody used to IHC showed that the tumor proliferation in the BIRT377 group was slow (n = 3, *P < 0.05). D&F CD31 antibody staining showed decreased MVD in the BIRT377 group (n = 3, **P < 0.01). G&J Treg cells determined by flow and the percentage of Treg cells in the blood in the BIRT377 group (n = 4) and Control (n = 4, **P < 0.01). H&K. the percentage of Treg cells in the mesenteric lymph nodes in the BIRT377 group (n = 3) and control group (n = 4, **P < 0.01). I&L. The percentage of Treg cells in spleens in the BIRT377 group (n = 3) and control group (n = 3, **P < 0.01)

Full size image

LFA-1 and Foxp3 are highly correlated in skin cutaneous melanoma and other tumor patients

The above results suggested that LFA-1 (Itgal) knockout would suppress tumor growth and decrease Treg cell numbers. Next, we analyze the correlation between LFA-1 and Treg cells specific nuclear transcription factor (Foxp3) in skin cutaneous melanoma(SKCM) and immune cell infiltration in the TIMER tumor database. The results showed that LFA-1 was highly correlated with Foxp3 in SKCM (Fig. 5A), and the LFA-1 expression level is negatively associated with tumor cells purity and positively associated with the infiltration of CD4 + T cells and CD8 + T cells (Fig. 5B). Tumour purity is the proportion of cancer cells in the admixture [26]. At the same time, we used the GEPIA database to analyze the expression level of LFA-1 and Foxp3 in SKCM and in different clinic stages of SKCM. The results showed that LFA-1 and Foxp3 were both highly expressed in SKCM, the expression level of LFA-1 in tumor was high than normal tissues, and the expression was the highest in Stage I of SKCM (Fig. 5C&D). In addition, in patients with many cancer types, like Bladder Cancer (BLCA), Breast Cancer (BRCA), Cervical Cancer (CESC), Colon Cancer (COAD), Esophageal Cancer (ESCA), Head and Neck Cancer (HNSC), Kidney Clear Cell Carcinoma (KIRC), Kidney Papillary Cell Carcinoma (KIRP), Liver Cancer (LIHC), Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Rectal Cancer (READ), Melanoma (SKCM), Stomach Cancer (STAD), Thyroid Cancer (THCA), the LFA-1 expression is positively correlatedwith foxp3 in tumor tissue (Fig. 5E). The mRNA sequencing analysis obtained from clinical tumor databases are consistent with our results and support our data that LFA-1 is associated with Treg cells in tumor tissue (Fig. 6).

Fig. 5
figure 5

LFA-1 and Foxp3 are highly correlated in SKCM. A The correlation between the expression levels of LFA-1 and Foxp3 in SKCM obtained by using TIMER database (https://cistrome.shinyapps.io/timer/). B The Infiltration levels of CD4 + T cells and CD8 + T cells in SKCM was analyzed by using the TIMER database (it is the proportion of cancer cells in the admixture. The gene expression levels against tumor purity are always displayed on the left-most panel. Because genes highly expressed in the microenvironment are expected to have negative associations with tumor purity, while the opposite is expected for genes highly expressed in the tumor cells). C The expression levels of LFA-1 and Foxp3 in SKCM and normal tissues were analyzed by GEPIA database (http://gepia.cancer-pku.cn/). D The expression levels of LFA-1 in SKCM in different pathological stages were analyzed by GEPIA database. E The expression of LFA-1 is highly correlated with Foxp3 in Bladder Cancer (BLCA), Breast Cancer (BRCA), Cervical Cancer (CESC), Colon Cancer (COAD), Esophageal Cancer (ESCA), Head and Neck Cancer (HNSC), Kidney Clear Cell Carcinoma (KIRC), Kidney Papillary Cell Carcinoma (KIRP), Liver Cancer (LIHC), Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Rectal Cancer (READ), Melanoma (SKCM), Stomach Cancer (STAD), Thyroid Cancer (THCA) tumors. These data were obtained from GEPIA (http://gepia.cancer-pku.cn/) 

Full size image
Fig. 6
figure 6

LFA-1 inhibitors, like LFA-1 knockout, inhibit tumor growth and are associated with decreased Treg cells

Full size image

Discussion

Previous studies have shown that LFA-1 deficiency can produce a normal CTL response to viral infection but fails to reject immunogenic tumors [6]. Here, LFA-1 knockout suppressed the growth of intestinal tumors in Apc Min/+ mice and also inhibited subcutaneous tumor growth in mouse model,

simultaneously accompanied by a decrease in the number of Treg cells.

LFA-1 is regarded as a bidirectional signaling molecule that controls cytoskeleton-dependent T-cell activation and is not constitutively active until it binds to ICAM-1 [27, 28]. LFA-1 play an important role in specific immune suppression and tolerance, initial LFA-1-dependent formation of Treg aggregates on immature Dendritic cells (DCs) and subsequent LFA-1- and CTLA-4-dependent active down-modulation of CD80/86 expression on DCs [29]. Treg cells have a crucial role in the immune system by preventing autoimmunity and limiting immunopathology. Importantly, they constitute a major barrier to effective antitumor immunity and sterilizing immunity to chronic viral infections [8]. Treg cells were impaired in LFA-1−/− mice, as confirmed in previous studies [5, 29,30,31]. Our results indicated an abnormal number of Treg cells in the mesenteric lymph nodes of LFA-1−/− mice. David P. et al. proved that LFA-1 regulates the transport of lymphocytes to peripheral lymph nodes and to a lesser extent to mesenteric lymph nodes and acute inflammatory sites [32]. LFA-1 is required for optimal CD4 + T cell priming in vivo [33]. However, CD4 + T cell upregulation is insufficient for antitumor effects [34]. Overall, these findings support our results that the number of Treg cells is decreased in LFA-1−/− mice, but the mechanism remains unclear.

Moreover, the analysis of the GEPIA database showed that the expression levels of LFA-1 and the Treg cell transcription factor Foxp3 are interrelated in numerous tumors in our study. Still, other immune cells cannot be excluded from participating in the immune response during tumor growth. In addition, another study showed that blockade of CD18 (an LFA-1 subtype) can impair melanoma cell transmigration to control the metastatic mechanism in melanoma [35], which also supported our results.

LFA-1 inhibitors have been reported; BIRT377, a member of a novel class of low-molecular-weight hydantoins, is the first small molecule inhibitor of LFA-1 and may have potential as a therapeutic agent [36, 37]. BIRT377 has been shown to block the binding of LFA-1/ICAM-1 and inhibit the interaction between T cells and antigen-presenting cells [19, 36, 38]. Blocking LFA-1 in the spinal cord with BIRT377 can eliminate allodynia in prenatal alcohol exposure (PAE) rats with sciatic neuropathy (CCI) for 10 or 28 days. BIRT377 can antagonize the effect of LFA-1 on reducing peripheral cell migration and may directly change the inflammatory bias of cells [20, 39, 40]. In our study, we showed that BIRT377, retard the growth of subcutaneous tumors and decrease the number of Treg cells.

LFA-1 deficiency is in all cell of the body and that its inhibitors are active on every cells bearing the target. In order to compare the immune function of LFA-1 negative Treg cells and wild-type Treg cells, we transplanted the bone marrow of LFA-1−/− mice and C57 mice into Rag-1−/− mice by tail vein surgery. Rag-1−/− mice showed severe early development retardation of T/B cells. we transplanted bone marrow of LFA-1−/− mice through tail vein into Rag-1−/− mice (4 mice), and bone marrow of C57 mice as control transplanting into another group of Rag-1−/− mice (4 mice). During the first week after transplantation, both groups of mice were well. But one week later, two Rag-1−/− mice transplanted with bone marrow of C57 mice died. By the third week, all the mice in this group were dead. However, these 4 mice that received bone marrow transplantation from LFA-1−/− mice stayed alive (Supplementary Fig. 3). This data demonstrates that LFA-1 deletion contributed to prolonging the survival rate of Rag-1−/− mice after bone marrow transplant. the reason keeps unknow. It is suggested that LFA-1 plays an important role in immune reaction. Indeed, so far, the limitation of the study is that it is difficult to neutralize and depleted Treg cells to confirm the effects and function of Treg cells in LFA-1−/− mice.

In conclusion, our findings reveal the new role of LFA-1 in tumors growth in mice is that the deletion of LFA-1 inhibits tumor growth. In addition, the decrease of Treg cells and the changes of related cytokines may help to inhibit tumor growth. It speculates that LFA-1 is a potential and promising biomarker for evaluating tumor growth and a novel target for tumor immunotherapy.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

LFA-1:

Lymphocyte function-associated antigen-1

Treg:

Regulatory T cells

EAE:

Experimental autoimmune encephalomyelitis

CTL:

Cytoxic T-cell lymphocyte

ICAM-1:

Intercellular adhesion molecule 1

H&E:

Hematoxylin-Eosin staining

IHC:

Immunohistochemistry

DAB:

Diaminobenzidine

MVD:

Microvascular density

FCM:

Flow cytometry analysis

PBS:

Phosphate-buffered saline

FBS:

Fetal bovine serum

GAPDH:

Glyceraldehyde 3-phosphate dehydrogenase

qRT-PCR:

Quantitative reverse transcription-polymerase chain reaction

SKCM:

Skin cutaneous melanoma

References

  1. Reina M, Espel E. Role of LFA-1 and ICAM-1 in Cancer. Cancers (Basel). 2017;9(11):153. https://doi.org/10.3390/cancers9110153.

  2. Vadillo E, et al. T cell acute lymphoblastic leukemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood Rev. 2018;32(1):36–51.

    Article  CAS  PubMed  Google Scholar 

  3. Vazquez Rodriguez G, et al. Estradiol promotes breast Cancer Cell Migration via Recruitment and activation of neutrophils. Cancer Immunol Res. 2017;5(3):234–47.

    Article  CAS  PubMed  Google Scholar 

  4. Dugger KJ, et al. Effector and suppressor roles for LFA-1 during the development of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2009;206(1–2):22–7.

    Article  CAS  PubMed  Google Scholar 

  5. Gultner S, et al. Reduced Treg frequency in LFA-1-deficient mice allows enhanced T effector differentiation and pathology in EAE. Eur J Immunol. 2010;40(12):3403–12.

    Article  PubMed  Google Scholar 

  6. Schmits R, et al. LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J Exp Med. 1996;183(4):1415–26.

    Article  CAS  PubMed  Google Scholar 

  7. Delgoffe GM, et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature. 2013;501(7466):252–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Walling BL, Kim M. LFA-1 in T Cell Migration and differentiation. Front Immunol. 2018;9:952.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Smith A, et al. The role of the integrin LFA-1 in T-lymphocyte migration. Immunol Rev. 2007;218:135–46.

    Article  CAS  PubMed  Google Scholar 

  11. Koboziev I, et al. Role of LFA-1 in the activation and trafficking of T cells: implications in the induction of chronic colitis. Inflamm Bowel Dis. 2012;18(12):2360–70.

    Article  PubMed  Google Scholar 

  12. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol. 2006;101(2):385–98.

    Article  PubMed  Google Scholar 

  13. Schell MJ, et al. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nat Commun. 2016;7:11743.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sakai E, et al. Combined mutation of apc, Kras, and Tgfbr2 effectively drives metastasis of Intestinal Cancer. Cancer Res. 2018;78(5):1334–46.

    Article  CAS  PubMed  Google Scholar 

  15. Erdman SE, et al. CD4 + CD25 + regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res. 2005;65(10):3998–4004.

    Article  CAS  PubMed  Google Scholar 

  16. Erdman SE, et al. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res. 2003;63(18):6042–50.

    CAS  PubMed  Google Scholar 

  17. Erdman SE, et al. CD4 + CD25 + regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol. 2003;162(2):691–702.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kelly TA, et al. Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. J Immunol. 1999;163(10):5173–7.

    Article  CAS  PubMed  Google Scholar 

  19. Hosseini BH, et al. Immune synapse formation determines interaction forces between T cells and antigen-presenting cells measured by atomic force microscopy. Proc Natl Acad Sci U S A. 2009;106(42):17852–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Sanchez JJ, et al. Targeting the beta2-integrin LFA-1, reduces adverse neuroimmune actions in neuropathic susceptibility caused by prenatal alcohol exposure. Acta Neuropathol Commun. 2019;7(1):54.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Ramachandran IR, et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol. 2013;190(7):3815–23.

    Article  CAS  PubMed  Google Scholar 

  22. Yu J, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783–97.

    Article  CAS  PubMed  Google Scholar 

  23. Basso D, Fogar P, Plebani M. The S100A8/A9 complex reduces CTLA4 expression by immature myeloid cells: implications for pancreatic cancer-driven immunosuppression. Oncoimmunology. 2013;2(6):9.

    Article  Google Scholar 

  24. Benchetrit F, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 2002;99(6):2114–21.

    Article  CAS  PubMed  Google Scholar 

  25. Tazawa K, et al. The effect of different anesthetics on tumor cytotoxicity by natural killer cells. Toxicol Lett. 2017;266:23–31.

    Article  CAS  PubMed  Google Scholar 

  26. Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015;6:8971.

    Article  CAS  PubMed  Google Scholar 

  27. Evans R, et al. Integrins in immunity. J Cell Sci. 2009;122(Pt 2):215–25.

    Article  CAS  PubMed  Google Scholar 

  28. Billadeau DD, Nolz JC, Gomez TS. Regulation of T-cell activation by the cytoskeleton. Nat Rev Immunol. 2007;7(2):131–43.

    Article  CAS  PubMed  Google Scholar 

  29. Onishi Y, et al. Foxp3 + natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008;105(29):10113–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Wang Y, et al. A critical role of LFA-1 in the development of Th17 cells and induction of experimental autoimmune encephalomyelytis. Biochem Biophys Res Commun. 2007;353(4):857–62.

    Article  CAS  PubMed  Google Scholar 

  31. Reisman NM, et al. LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function. Blood. 2011;118(22):5851–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Andrew DP, et al. Transendothelial migration and trafficking of leukocytes in LFA-1-deficient mice. Eur J Immunol. 1998;28(6):1959–69.

    Article  CAS  PubMed  Google Scholar 

  33. Kandula S, Abraham C. LFA-1 on CD4 + T cells is required for optimal antigen-dependent activation in vivo. J Immunol. 2004;173(7):4443–51.

    Article  CAS  PubMed  Google Scholar 

  34. Penaloza-MacMaster P, et al. Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection. Science. 2015;347(6219):278–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ghislin S, et al. LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro. BMC Cancer. 2012;12:455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Larson RS, et al. Dissociation of I domain and global conformational changes in LFA-1: refinement of small molecule-I domain structure-activity relationships. Biochemistry. 2005;44(11):4322–31.

    Article  CAS  PubMed  Google Scholar 

  37. Last-Barney K, et al. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein–protein interaction. J Am Chem Soc. 2001;123(24):5643–50.

    Article  CAS  PubMed  Google Scholar 

  38. Woska JR Jr, et al. A small-molecule antagonist of LFA-1 blocks a conformational change important for LFA-1 function. J Leukoc Biol. 2001;70(2):329–34.

    Article  PubMed  Google Scholar 

  39. Noor S, Sun MS, Vanderwall AG, Havard MA, Sanchez JE, Harris NW, Nysus MV, Norenberg JP, West HT, Wagner CR, Jantzie LL, Mellios N, Milligan ED. LFA-1 antagonist (BIRT377) similarly reverses peripheral neuropathic pain in male and female mice with underlying sex divergent peripheral immune proinflammatory phenotypes. Neuroimmunol Neuroinflamm. 2019;6:10. https://doi.org/10.20517/2347-8659.2019.18.

  40. Noor S, et al. The LFA-1 antagonist BIRT377 reverses neuropathic pain in prenatal alcohol-exposed female rats via actions on peripheral and central neuroimmune function in discrete pain-relevant tissue regions. Brain Behav Immun. 2020;87:339–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Dr. Zhang Qianqian, Qi Cuiling and Zheng Lingyun for advice in our manuscript and data analysis.

Funding

This work was supported by grants from the National Natural Science Foundation of China (Grant ID: 81773118 to Jiangchao Li, 31771578 to Lijing Wang and the National Key R&D Program of China 2021YFF0702600).

Author information

Author notes

  1. Ting Niu and Zhengyang Li contributed equally to this work.

Authors and Affiliations

  1. Institute of Basic Medical Sciences, School of Life Sciences and Biopharmaceuticals, Guangdong Pharmaceutical University, No. 280 Waihuan Rd. E, Higher Education Mega Center, 510006, Guangzhou, China

    Ting Niu, Zhengyang Li, Yiting Huang, Yuxiang Ye, Yilong Liu, Zhijin Ye, Lingbi Jiang, Xiaodong He, Lijing Wang & Jiangchao Li

Authors
  1. Ting Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhengyang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yiting Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuxiang Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yilong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhijin Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lingbi Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaodong He
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lijing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jiangchao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LZY, LJC and WLJ conception idea and scheme design. NT, LZY, YYX, HYT, YZJ, and LYL acquisition of experiments data. LZY, NT, HYT, and YYX data statistics and analysis. LZY, NT, HYT, JLB and LJC writing and revising manuscripts. HYT, HXD, NT, and LZY manage transgenic mice. LJC and WLJ supervision and Funding. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Lijing Wang or Jiangchao Li.

Ethics declarations

Ethics approval and consent to participate

All mice were housed in the specific pathogen-free barrier facility of Animal Center of Guangdong Pharmaceutical University with license number SCYK (Guangdong) 2017 − 0125. The Animal Ethics Review Committee approves all Guangdong Pharmaceutical University animal experiments; the animal ethics approval number is Gdpulac20177006.

Consent for publication

The consents for publication from all authors were obtained.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niu, T., Li, Z., Huang, Y. et al. LFA-1 knockout inhibited the tumor growth and is correlated with treg cells. Cell Commun Signal 21, 233 (2023). https://doi.org/10.1186/s12964-023-01238-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12964-023-01238-6

Keywords

Cell Communication and Signaling

ISSN: 1478-811X